ReviewDiabetes & metabolism journal2016
Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis.
Review in Diabetes & metabolism journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Relationship between prevalence and risk of osteoporosis or osteoporotic fracture with non-alcoholic fatty liver disease: A systematic review and meta-analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022Pooled it
- Diagnosis and Management of Pediatric Non-Alcoholic Fatty Liver Disease: An Overview.Metabolites · 2025Review
- AMPK-Targeting Effects of (-)-Epicatechin Gallate fromInternational journal of molecular sciences · 2025Article
- Exogenous HScientific reports · 2025Article
- Exosome GLUT1 derived from hepatocyte identifies the risk of non-alcoholic steatohepatitis and fibrosis.Hepatology international · 2023Article
- β-sitosterol attenuates high- fat diet-induced hepatic steatosis in rats by modulating lipid metabolism, inflammation and ER stress pathway.BMC pharmacology & toxicology · 2023Article
- Role of extracellular vesicles in nonalcoholic fatty liver disease.Frontiers in endocrinology · 2023Review
- Angiopoietin-2 levels correlates with disease activity in children with nonalcoholic fatty liver disease.Pediatric research · 2022Article
- Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway.Scientific reports · 2021Article
- TWIST2 and the PPAR signaling pathway are important in the progression of nonalcoholic steatohepatitis.Lipids in health and disease · 2021Article
- Effects of Oral Vitamin C Supplementation on Liver Health and Associated Parameters in Patients With Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial.Frontiers in nutrition · 2021Article
- Orotic acid-treated hepatocellular carcinoma cells resist steatosis by modification of fatty acid metabolism.Lipids in health and disease · 2020Article
- Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer.Journal of hematology & oncology · 2019Review
- Curcumin Recovers Intracellular Lipid Droplet Formation Through Increasing Perilipin 5 Gene Expression in Activated Hepatic Stellate Cells In Vitro.Current medical science · 2019Article
- PPAR δ inhibition protects against palmitic acid-LPS induced lipidosis and injury in cultured hepatocyte L02 cell.International journal of medical sciences · 2019Article
- Lipid mediators of liver injury in nonalcoholic fatty liver disease.American journal of physiology. Gastrointestinal and liver physiology · 2019Review
- Can obesity-induced inflammation in skeletal muscle and intramuscular adipose tissue accurately detect liver fibrosis?Journal of musculoskeletal & neuronal interactions · 2018Article
- Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASH.Clinical and experimental immunology · 2018Review
- Apoptosis and non-alcoholic fatty liver diseases.World journal of gastroenterology · 2018Review
- Efficient scalable production of therapeutic microvesicles derived from human mesenchymal stem cells.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease in adults and children worldwide. NAFLD has become a severe health issue and it can progress towards a more severe form of the disease, the non-alcoholic steatohepatitis (NASH). A combination of environmental factors, host genetics, and gut microbiota leads to excessive accumulation of lipids in the liver (steatosis), which may result in lipotoxicity and trigger hepatocyte cell death, liver inflammation, fibrosis, and pathological angiogenesis. NASH can further progress towards liver cirrhosis and cancer. Over the last few years, cell-derived extracellular vesicles (EVs) have been identified as effective cell-to-cell messengers that transfer several bioactive molecules in target cells, modulating the pathogenesis and progression of NASH. In this review, we focused on recently highlighted aspects of molecular pathogenesis of NASH, mediated by EVs via their bioactive components. The studies included in this review summarize the state of art regarding the role of EVs during the progression of NASH and bring novel insight about the potential use of EVs for diagnosis and therapeutic strategies for patients with this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.